[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.161.130.145. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Grand Rounds
Clinician's Corner
September 17, 2008

Neurologic Manifestations of von Hippel-Lindau Disease

Author Affiliations

Author Affiliations: Diagnostic Radiology Department, The Clinical Center of the National Institutes of Health, Bethesda, Maryland (Dr Butman); Urologic Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health (Dr Linehan); and Surgical Neurology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health (Dr Lonser).

JAMA. 2008;300(11):1334-1342. doi:10.1001/jama.300.11.1334
Abstract

von Hippel-Lindau disease (VHL) is an autosomal-dominant neoplasia syndrome that is the result of a germline mutation of the VHL tumor suppressor gene on the short arm of chromosome 3. Patients with VHL are predisposed to develop lesions of the central nervous system and viscera. Central nervous system lesions include hemangioblastomas (the most common tumor in VHL) and endolymphatic sac tumors (ELSTs). Visceral manifestations include renal carcinomas and cysts, pancreatic neuroendocrine tumors and cysts, pheochromocytomas, and cystadenomas of the reproductive adnexal organs. Despite their benign pathology, hemangioblastomas and ELSTs are a frequent cause of morbidity and mortality in patients with VHL. Recent molecular biologic investigations into these VHL-associated central nervous system lesions provide new insight into their origin and development. Emerging data from serial imaging and clinical surveillance protocols provide insight into the natural history of these lesions. Because of the dissimilar pathobiology and clinical course between hemangioblastomas and ELSTs, the optimal management strategies for these neurologic manifestations of VHL are very different.

×